drugset
drugset / Trial / NCT04973098

Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma

NCT04973098 ↗

Phase 1 Unknown 13 enrolled Peking University CARsgen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

A Phase I Clinical Study of CT0181 cells in Patients with Advanced Hepatocellular Carcinoma

Timeline

Start
2021-08-05
Primary completion
2022-08
Completion
2023-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CT0181 Cell therapy — —

Indications

hepatocellular carcinoma